Navigation Links
Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone

competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:

    Dan Eramian

    T: 206.272.4343

    C: 206.854.1200


    Susan Callahan

    T: 206.272.4472

    F: 206.272.4434

    E: 

    http://www.cticseattle.com/media.htm


    Investors Contact:

    Leah Grant

    T: 206.282.7100

    F: 206.272.4434

    E: 

    http://www.cticseattle.com/investors.htm


    Medical Information Contact:

    T: 800.715.0944

    E: 

media@ctiseattle.com invest@ctiseattle.com info@askarm.com

CONTACT: Media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200, forCell Therapeutics, Inc.; or Susan Callahan, +1-206-272-4472,, or Investors, Leah Grant, +1-206-282-7100,, both of Cell Therapeutics, Inc., fax,+1-206-272-4434; or Medical Information, 1-800-715-0944, media@ctiseattle.com invest@ctiseattle.com info@askarm.com

Web site: http://www.cticseattle.com/

Ticker Symbol: (NASDAQ-NMS:CTIC
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind ... Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ ... zu besuchen. Diese Tagung soll ... die Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, ...
(Date:12/15/2014)... -- BerGenBio AS, a biopharmaceutical company focused ... today announces that it has raised NOK90 million (c. ... existing investors. BerGenBio will use the proceeds ... pipeline of innovative cancer therapeutics, in particular an enlarged ... a first-in-class selective Axl kinase inhibitor, which is currently ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2BerGenBio Completes NOK90 Million Fundraising 2
... Anaphore Inc. today announced that the company ... Corporation (Osaka, Japan) for the research, development and commercialization ... The partnership will be based on ... called Atrimers(TM ) with binding domains that can ...
... MISSISSAUGA, Ontario, Dec. 13, 2010 Valeant Pharmaceuticals International, ... announced that Robert A. Ingram, Valeant,s lead independent director, ... replacing William M. Wells, who has resigned from the ... About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is ...
Cached Medicine Technology:Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders 2Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders 3
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic alliance ... Ocean Avenue has secured exclusive benefit to the strategic ... JM Ocean Avenue is a direct sales company ... and JM International, with partial ownership coming from JM ... , “After nearly 2 decades of servicing the industry ...
(Date:12/15/2014)... South Florida’s leading urgent care provider, ... a daze of hassle, hustle, and bustle that can cause ... to burns when making special meals and heartburn after eating ... at any time. To prevent this season of joy from ... list of helpful and healthful holiday tips to keep the ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. 12, 2014 ... millions of American women who have migraine: The debilitating headaches ... no association between migraine and breast cancer risk," said lead ... Medical School. "There is no positive association, so there is ... either." About 18 percent of American women and 6 ...
(Date:12/15/2014)... 15, 2014 The increase in prevalence of ... the main factors which is contributing to the growth in ... diagnosis and treatment of hearing loss and balance disorders are ... parts - microphone, speaker and amplifier. The global market is ... 6.01% during the period from 2014 to 2019. Some of ...
Breaking Medicine News(10 mins):Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... than 600,000 children participate in school-sponsored and club-level gymnastics ... to be overlooked in terms of potential for injury, ... all girls sports. , A study, conducted by researchers ... at The Research Institute at Nationwide Childrens Hospital and ...
... Barker to Create Gallery of Beautiful ... Smiles Curated by Gen Art, ... To celebrate the launch of a new generation of,smile care, Crest ... for your smile to whiten and protect against,tartar build-up -- Crest ...
... the American Correctional Association Auditors ... High Praise From Board Chair Romanowicz, CENTRAL FALLS, ... and examination by the American Correctional Association,Commission on Accreditation, ... that the Donald W. Wyatt Detention,Facility has passed with ...
... Risk, BALTIMORE, April 4, 2008 Newly published ... Journal shows a 50% reduction,of type 2 diabetes occurred ... a vaccine to prevent tuberculosis.,This decline occurred at a ... 2,diabetes and metabolic syndrome, which includes obesity, altered blood,cholesterol ...
... April 4 at Ralphs Pharmacies Throughout Southern California, ... will,begin offering pharmacy customers generic drugs for $4 per ... price will apply to hundreds of generic drugs prescribed ... in Ralphs stores,throughout Southern California. A list of the ...
... To promote,the U.S. Department of Health and ... initiative, Acting U.S. Surgeon General Rear Admiral ... community leaders at A.I.,DuPont Hospital for Children ... in Delaware., (Photo: httphttp://www.newscom.com/cgi-bin/prnh/20080403/18521), The ...
Cached Medicine News:Health News:The Quest for America's Life in Beautiful Smiles: Captured in Photography 2Health News:The Quest for America's Life in Beautiful Smiles: Captured in Photography 3Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 2Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 3Health News:Vaccine Induced Inflammation Linked to Epidemic of Type 2 Diabetes and Metabolic Syndrome 2Health News:Ralphs Introduces $4 Generic Drugs 2Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 2Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: